Early Deafness Rewires Brain for Wider Peripheral Vision
A new study shows that people deaf from an early age develop enhanced peripheral vision, a neural adaptation that may act as a built-in danger detector.
Researchers report that individuals who became deaf early in life exhibit a measurable boost in peripheral vision, a result of the brain reallocating resources usually devoted to hearing. The study, described as pioneering, found that this rewiring allows them to take in more of what happens at the edges of their visual field, effectively widening their awareness of the surrounding environment.
The effect is linked to the developmental window in which hearing is lost. The brains of these individuals appear to repurpose areas that would normally process sound to instead handle visual input, strengthening the ability to detect motion and objects off to the side. This enhanced sensitivity to the periphery has been compared to a 'danger radar,' as it may offer a survival advantage by making threats or changes in the environment more noticeable.
While the findings highlight the brain's flexibility in adapting to sensory loss, the research does not specify whether the improvement comes with any trade-offs in central vision or other cognitive functions. The authors suggest that further work could explore how this adaptation develops and whether similar changes occur in other sensory modalities, but the current evidence points to a clear, beneficial reshaping of visual processing in the deaf population.
More in Medicine & Biotech
Ebola Vaccine Trial Launches in DR Congo Outbreak Zone
Health workers in DR Congo have begun testing whether a vaccine designed for a different Ebola strain can protect against the current outbreak.
Beacon Gene Therapy for Rare Vision Loss Succeeds in Pivotal Trial
A pivotal trial of Beacon Therapeutics' gene therapy for X-linked retinitis pigmentosa improved visual acuity, clearing the path toward an FDA submission.
Alkermes orexin agonist shows early promise for ADHD
Early-stage data suggest Alkermes' orexin agonist could expand the drug class beyond sleep disorders into ADHD.
Telix to Buy ITM for $1.65B, Challenging Novartis in Radiopharma
The acquisition gives Telix a late-stage pipeline and supply network that could compete with Novartis' Lutathera.